The Nasdaq Now: Tranzyme Collapses After Drug Trial Failure – Minyanville.com
|
The Nasdaq Now: Tranzyme Collapses After Drug Trial Failure
Minyanville.com Shares of NetApp (NASDAQ:NTAP) surged 10.57% to $ 29.99 after an upgrade to Outperform from Market Perform from Raymond James analyst Brian Alexander. In his note, Alexander wrote that his firm has “increased optimism that product refreshes, tighter … |
